Watch These Hot Ones: Halozyme Therapeutics, Inc., ARRIS International plc (NASDAQ:ARRS), Five Prime Therapeutics (NASDAQ:FPRX), Osiris Therapeutics (NASDAQ:OSIR)

On 15 January, SINA Corporation (NASDAQ:SINA) shares decreased -4.70% and was closed at $44.82. SINA EPS growth in last 5 year was -18.70%. SINA Corporation (NASDAQ:SINA) year to date (YTD) performance is -9.27%.

On 12 January, SINA Corporation (NASDAQ:SINA) and its majority-owned subsidiary Weibo Corporation (“Weibo”) (NASDAQ: WB), China’s leading social media platform, announced recent changes of their respective boards of directors. Mr. Pehong Chen has ceased to be a director of SINA and instead began to serve on the board of directors of Weibo, replacing Mr.Yichen Zhang, who resigned from Weibo’s board.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares decreased -1.08% in last trading session and ended the day at $10.10. HALO Gross Margin is 76.10% and its has a return on assets of -25.50%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -30.82%.

On 11 January Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided key program updates and its Annual financial guidance at the 34 annual .

On 15 January, ARRIS International plc (NASDAQ:ARRS) shares decreased -5.68% and was closed at $26.42. ARRS EPS growth in last 5 year was 35.22%. ARRIS International plc (NASDAQ:ARRS) year to date (YTD) performance is -13.58%.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shares increased 0.06% in last trading session and ended the day at $33.62. FPRX has a return on assets of -29.50%. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) quarterly performance is 20.37%.

On 11 January, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) provided an update on GlaxoSmithKline’s (GSK) ongoing Phase 1b clinical trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non-small cell lung cancer (sqNSCLC) and mesothelioma.

Osiris Therapeutics, Inc. (NASDAQ:OSIR) caters to the Healthcare space. It has a net profit margin of 3.20% and weekly performance is -25.18%. On the last day of trading company shares ended up at $7.28. Osiris Therapeutics, Inc. (NASDAQ:OSIR) distance from 50-day simple moving average (SMA50) is -9.07%.

Zacks Investment Research upgraded shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) from a sell rating to a hold rating in a research report released on Wednesday morning, MarketBeat reports.